AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30789785
Drug: Providing detailed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Providing detailed process information about conflict resolution in withholding treatment (second opinion, ethics consultation, exploring transfer to another institution)
Trial: 30198057
Drug: Resminostat plus
RxNorm normalized name: resminostat
DrugBank: Resminostat (DB12392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resminostat plus sorafenib (resminostat 400 mg/day on days 1 to 5 every 14 days, sorafenib 800 mg/day for 14 days)
Trial: 30198057
Drug: Sorafenib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib monotherapy (800 mg/day)
Trial: 30198057
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (resminostat plus sorafenib)
Trial: 30198057
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (resminostat plus sorafenib) among patients with normal-to-high baseline platelet count (≥ 150 × 103/mm3)
Trial: 30198057
Drug: Sorafenib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib monotherapy among patients with normal-to-high baseline platelet count (≥ 150 × 103/mm3)
Trial: 27521970
Drug: Oxycodone and
RxNorm normalized name: oxycodone and naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone and dexmedetomidine (group OD)
Trial: 27521970
Drug: Oxycodone alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone alone (group O)
Trial: 25561816
Drug: Gemcitabine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine and S‐1 combination therapy (recurrent group)
Trial: 25561816
Drug: Gemcitabine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine and S‐1 combination therapy (unresectable group)
Trial: 20215710
Drug: Intensive lipid-lowering
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive lipid-lowering therapy with rosuvastatin (target LDL-C levels: 80 mg/dL for primary prevention, 70 mg/dL for secondary prevention)
Trial: 20215710
Drug: Conventional lipid-lowering
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional lipid-lowering therapy with pravastatin (target LDL-C level: complying with JASGL2007)
Trial: 19469273
Drug: Hormonal therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal therapy (2 mg of estradiol and 0.5 mg of norgestrel)
Trial: 15916866
Drug: L-methadone
RxNorm normalized name: dl-Methadone
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-methadone
Trial: 15916866
Drug: D,L-methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D,L-methadone
Trial: 12428068
Drug: Bismuth subnitrate
RxNorm normalized name: Bismuth subnitrate
DrugBank: Bismuth subnitrate (DB13209)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth subnitrate plus metronidazole and amoxicillin (group A)
Trial: 12428068
Drug: Eradication therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eradication therapy after 3 months for group B non-responders
Trial: 8880666
Drug: substance abuse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: substance abuse treatment without case management
Trial: 26898340
Drug: Gentamicin impregnated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin impregnated collagen sponge (GICS) at gentamicin dose = 6 mg/kg (n = 9)
Trial: 23893101
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment (PEERS intervention)
Trial: 17924889
Drug: Fentanyl bolus
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl bolus administration
Trial: 9024516
Drug: Heparin solution
RxNorm normalized name: heparin Injectable Solution
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin solution (25 U/ml) with vancomycin (25 mcg/ml) for daily catheter flush (HepVan)
Trial: 9024516
Drug: Heparin solution
RxNorm normalized name: heparin Injectable Solution
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin solution (25 U/ml) without vancomycin (Hep)
Trial: 3101502
Drug: Viscoelastic tear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viscoelastic tear formulations (including hyaluronic acid and chondroitin sulfate)
Trial: 3101502
Drug: Chondroitin sulfate
RxNorm normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chondroitin sulfate solution
Trial: 3101502
Drug: Polyvinyl alcohol
RxNorm normalized name: Polyvinyl Alcohol
DrugBank: Polyvinyl alcohol (DB11060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polyvinyl alcohol or hyaluronic acid solution
Trial: 31199766
Drug: Dysentery compound
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dysentery compound (DC)
Trial: 16389165
Drug: Intravenous lignocaine
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lignocaine (5 mg/kg)
Trial: 16389165
Drug: Intravenous lignocaine
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lignocaine (7.5 mg/kg)
Trial: 23178468
Drug: Somatostatin administration
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin administration
Trial: 9059166
Drug: Preci-Jet 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preci-Jet 50 transjector for growth hormone delivery
Trial: 9059166
Drug: Pen injection
RxNorm normalized name: Autopen Injection Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pen injection system for growth hormone delivery
Trial: 8377957
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose methotrexate, 15 mg weekly
Trial: 2439786
Drug: Bisoprolol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol (20 mg)
Trial: 27524403
Drug: Individual pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual pain treatment for eight weeks
Trial: 24554388
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose of 50‐60 min of aerobic exercise (HIGH; n = 101)
Trial: 24554388
Drug: Combined dose
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined dose of 50‐60 min of aerobic and resistance exercise (COMB; n = 104)
Trial: 24554388
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of 25‐30 min of aerobic exercise (STAN; n = 96)
Trial: 23301468
Drug: Acupuncture +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture + medication (electroacupuncture at Baihui, Yintang, Sishencong, Taichong, Sanyinjiao) with oral administration of madopar and fluoxetine
Trial: 23301468
Drug: Medication (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (oral administration of madopar and fluoxetine)
Trial: 20522567
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of lidocaine and bupivacaine
Trial: 9163278
Drug: S-(+)-ketamine 1
RxNorm normalized name: (S)-(-)-ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-(+)-ketamine 1 mg/kg
Trial: 9163278
Drug: Ketamine racemate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine racemate 2 mg/kg
Trial: 9163278
Drug: S-(+)-ketamine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-(+)-ketamine 0.5 mg/kg
Trial: 9163278
Drug: Ketamine racemate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine racemate 1 mg/kg
Trial: 9163278
Drug: S-(+)-ketamine 2
RxNorm normalized name: (S)-(-)-ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-(+)-ketamine 2 mg/kg
Trial: 9163278
Drug: Ketamine racemate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine racemate 4 mg/kg
Trial: 9163278
Drug: S-(+)-ketamine 1
RxNorm normalized name: (S)-(-)-ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-(+)-ketamine 1 mg/kg with midazolam
Trial: 9163278
Drug: Ketamine racemate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine racemate 2 mg/kg with midazolam
Trial: 8369784
Drug: Fixed-triple combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-triple combination of isoniazid (750 mg), rifampicin (600 mg), and pyrazinamide (2,250 mg)
Trial: 8369784
Drug: Individual administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual administration of isoniazid (750 mg), rifampicin (600 mg), and pyrazinamide (2,250 mg)
Trial: 31063574
Drug: Aspirin 300
RxNorm normalized name: aspirin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 300 mg (n=1208)
Trial: 28750737
Drug: 10 ppm
RxNorm normalized name: Glycerin 1.0 g in 25 mL TOPICAL CREAM [EGF Crystal 10 ppm]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ppm NO inhalation
Trial: 18640991
Drug: ET-1 infusion
RxNorm normalized name: coagulation factor IX recombinant immunoglobulin G1 fusion protein 1 UNT [Alprolix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ET-1 infusion (1.0-2.5 ng kg(‐1) min(‐1))
Trial: 11028255
Drug: Promethazine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promethazine (50 mg)
Trial: 1672059
Drug: isostop group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: isostop group (isoflurane discontinued before neostigmine administration)
Trial: 6839001
Drug: compressed ASA
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: compressed ASA tablets (cASA)
Trial: 6839001
Drug: sodium salicylate
RxNorm normalized name: Sodium Salicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sodium salicylate (578 mg)
Trial: 30639991
Drug: Group CBTp
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group CBTp plus treatment as usual (TAU)
Trial: 30480729
Drug: Lanadelumab 150
RxNorm normalized name: Lanadelumab 150 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanadelumab 150 mg every 4 weeks (n=28)
Trial: 30480729
Drug: Lanadelumab 300
RxNorm normalized name: lanadelumab 300 mg in 2 mL SUBCUTANEOUS SOLUTION [TAKHZYRO]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanadelumab 300 mg every 4 weeks (n=29)
Trial: 30480729
Drug: Lanadelumab 300
RxNorm normalized name: lanadelumab 300 mg in 2 mL SUBCUTANEOUS SOLUTION [TAKHZYRO]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanadelumab 300 mg every 2 weeks (n=27)
Trial: 25665812
Drug: Supplemental insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supplemental insulin at bedtime for blood glucose (BG) >7.8 mmol/L
Trial: 25665812
Drug: No supplemental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No supplemental insulin except for BG >19.4 mmol/L
Trial: 25665812
Drug: Supplemental insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supplemental insulin at bedtime
Trial: 25665812
Drug: No supplemental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No supplemental insulin
Trial: 24814472
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment (mindfulness-based therapy)
Trial: 19181486
Drug: antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antibiotic therapy alone (prulifloxacin 600 mg daily for 14 days)
Trial: 12133539
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) at a dosage of 1.0 - 1.5 g/d
Trial: 12133539
Drug: Cyclophosphamide (CYC)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (CYC) pulse therapy
Trial: 30623248
Drug: Generic formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic formulation with amorphous form of BCS 2 class drug
Trial: 30623248
Drug: Reference drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference drug product with crystalline form
Trial: 17547760
Drug: Active strategy
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active strategy (training module with administration of the guideline)
Trial: 17547760
Drug: Passive dissemination
RxNorm normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive dissemination (administration of the guideline only)
Trial: 9861607
Drug: Chromium picolinate
RxNorm normalized name: Chromium Picolinate
DrugBank: Chromium picolinate (DB11255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chromium picolinate supplementation (200 micrograms daily)
Trial: 2192073
Drug: Pulse-dosed antibiotics
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse-dosed antibiotics administered in a single daily dose
Trial: 31335979
Drug: Insulin plus
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin plus liraglutide 0.6 mg/day
Trial: 28884856
Drug: Adalimumab trough
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab trough level of 5.0 μg/mL
Trial: 21641354
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no ABMMNC treatment)
Trial: 19254211
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy of IHD
Trial: 16442924
Drug: Clopidogrel (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (loading dose 300 mg followed by 75 mg/d for 8 weeks)
Trial: 15630287
Drug: Isoflavone supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone supplements (40mg/d)
Trial: 11332874
Drug: 1.12 mg
RxNorm normalized name: Kytril 1 MG (granisetron hydrochloride 1.12 MG) Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.12 mg chlorphenamine maleate (0.4% nasal spray)
Trial: 11332874
Drug: 2.24 mg
RxNorm normalized name: Kytril 2 MG (granisetron hydrochloride 2.24 MG) Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.24 mg chlorphenamine maleate (0.4% nasal spray)
Trial: 11332874
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg chlorphenamine maleate (tablets)
Trial: 9444443
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate aqueous nasal spray (MFNS) at 50, 100, or 200 micrograms once daily for 7 days
Trial: 9444443
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate aqueous nasal spray (MFNS) at 50, 100, or 200 micrograms once daily for 14 days
Trial: 10654982
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate aqueous nasal spray (MFNS)
Trial: 9037289
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of vasodilators
Trial: 9037289
Drug: Slow injection
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow injection of vasodilators
Trial: 9181442
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection
Trial: 9037289
Drug: Slow injection
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow injection of low volume drug
Trial: 2667859
Drug: Oral xylose
RxNorm normalized name: Xylose
DrugBank: Xylose (DB09419)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral xylose
Trial: 2667859
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose and xylose
Trial: 822547
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg rifampicin daily for 12 weeks followed by once-weekly for 12 months
Trial: 822547
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg rifampicin once-weekly for 12, 18 or 24 months
Trial: 822547
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg rifampicin for longer than 1 year
Trial: 9578186
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg rifampicin
Trial: 822547
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg rifampicin
Trial: 822547
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg rifampicin for 24 months
Trial: 16683672
Drug: 1% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% chlorhexidine gel with Ca(OH)2
Trial: 15459587
Drug: Intravenous adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous adenosine 140 microg/kg/min
Trial: 12959311
Drug: ACE inhibition
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibition with fosinopril, 20 mg day(‐1)
Trial: 2841818
Drug: estrogen-gestagen sequential
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: estrogen-gestagen sequential therapy
Trial: 2841818
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (all therapies)
Trial: 26108222
Drug: Oral lysergic
RxNorm normalized name: D-lysergic acid 1-butanolamide
DrugBank: Methylergometrine (DB00353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral lysergic acid diethylamide (200 μg)
Trial: 24074332
Drug: Combination budesonide/formoterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination budesonide/formoterol inhaler according to a single inhaler regimen (SMART)
Trial: 20461422
Drug: Alfacalcidol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfacalcidol (1 μg/day) + Alendronate (5 mg/day)
Trial: 16538542
Drug: Dose-dense sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dense sequential chemotherapy (3 cycles of epirubicin 110 mg/m2 followed by 3 cycles of paclitaxel 250 mg/m2 followed by 3 cycles of intensified CMF)
Trial: 16538542
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy (4 cycles of epirubicin followed by 4 cycles of CMF)
Trial: 14499022
Drug: Spiritual healing
RxNorm normalized name: Spiritus vini
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spiritual healing treatment (3 weekly sessions lasting approximately 30 minutes each)
Trial: 10920469
Drug: Risperidone (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (mean daily dose, 2.2 +/- 0.7 mg/d)
Trial: 8612028
Drug: SSZ (2g/day)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSZ (2g/day) and pulses of MP (5 mg/kg)
Trial: 6692287
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg tamoxifen daily
Trial: 29943719
Drug: PfSPZ Vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PfSPZ Vaccine (5 doses of 2.7 × 10^5 PfSPZ at 0, 4, 8, 12, and 20 weeks)
Trial: 27338955
Drug: TRABC in
RxNorm normalized name: atropine sulfate / benzoic acid / hyoscyamine sulfate / methenamine / methylene blue / phenyl salicylate Oral Tablet [Trac Tabs 2x]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRABC in addition to conventional Western treatment
Trial: 20353028
Drug: Conventional Western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Western treatment
Trial: 20191783
Drug: Interval between
RxNorm normalized name: CYCLIZED P12 (PEPTIDE BOND BETWEEN THE CARBOXY AND AMINO-TERMINAL ENDS OF THE LINEAR PEPTIDE PSHISKYILRWRPK)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interval between last dose of relaxant and arrival in PACU
Trial: 12025888
Drug: 10-min infusion
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-min infusion of topotecan (1.5 mg/m2/d for 5 days of a 21-day course)
Trial: 12025888
Drug: 10-min infusion
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-min infusion of topotecan
Trial: 2177970
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMH)